{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T01:27:32Z","timestamp":1779413252335,"version":"3.53.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15982-8","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T10:26:02Z","timestamp":1776162362000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world trends in diagnosis, treatment, and survival of non\u2013small cell lung cancer in Vietnam"],"prefix":"10.1186","volume":"26","author":[{"given":"Vinh Hung","family":"Pham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinh Chinh","family":"Duong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viet Binh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huyen Nga","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khanh Toan","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi Thuy My","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi Huong","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van Lam","family":"Ngo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van Tuan","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muoi Dang","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khanh Hung","family":"Truong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ba Duc","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van Nhat","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"issue":"3","key":"15982_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"15982_CR2","unstructured":"Cancer Today. Available from: https:\/\/gco.iarc.who.int\/today\/. [Cited 2026 Jan 10]."},{"issue":"7689","key":"15982_CR3","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature25183","volume":"553","author":"RS Herbst","year":"2018","unstructured":"Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446\u201354. https:\/\/doi.org\/10.1038\/nature25183.","journal-title":"Nature"},{"issue":"10","key":"15982_CR4","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or Carboplatin\u2013Paclitaxel in Pulmonary Adenocarcinoma. N Engl J Med. 2009;361(10):947\u201357. https:\/\/doi.org\/10.1056\/NEJMoa0810699.","journal-title":"N Engl J Med"},{"issue":"3","key":"15982_CR5","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","volume":"13","author":"R Rosell","year":"2012","unstructured":"Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239\u201346. https:\/\/doi.org\/10.1016\/S1470-2045(11)70393-X.","journal-title":"Lancet Oncol"},{"issue":"1","key":"15982_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC. N Engl J Med. 2020;382(1):41\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1913662.","journal-title":"N Engl J Med"},{"issue":"9","key":"15982_CR7","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1704795","volume":"377","author":"S Peters","year":"2017","unstructured":"Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, et al. Alectinib versus Crizotinib in Untreated ALK -Positive Non\u2013Small-Cell Lung Cancer. N Engl J Med. 2017;377(9):829\u201338. https:\/\/doi.org\/10.1056\/NEJMoa1704795.","journal-title":"N Engl J Med"},{"issue":"19","key":"15982_CR8","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, et al. Pembrolizumab versus Chemotherapy for PD-L1\u2013Positive Non\u2013Small-Cell Lung Cancer. N Engl J Med. 2016;375(19):1823\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1606774.","journal-title":"N Engl J Med"},{"issue":"22","key":"15982_CR9","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus Chemotherapy in Metastatic Non\u2013Small-Cell Lung Cancer. N Engl J Med. 2018;378(22):2078\u201392. https:\/\/doi.org\/10.1056\/NEJMoa1801005.","journal-title":"N Engl J Med"},{"issue":"20","key":"15982_CR10","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after Chemoradiotherapy in Stage III Non\u2013Small-Cell Lung Cancer. N Engl J Med. 2017;377(20):1919\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1709937.","journal-title":"N Engl J Med"},{"issue":"7","key":"15982_CR11","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJMoa2402614","volume":"391","author":"S Lu","year":"2024","unstructured":"Lu S, Kato T, Dong X, Ahn MJ, Quang LV, Soparattanapaisarn N, et al. Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC. N Engl J Med. 2024;391(7):585\u201397. https:\/\/doi.org\/10.1056\/NEJMoa2402614.","journal-title":"N Engl J Med"},{"issue":"1","key":"15982_CR12","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s12885-022-09342-5","volume":"22","author":"R Carroll","year":"2022","unstructured":"Carroll R, Bortolini M, Calleja A, Munro R, Kong S, Daumont MJ, et al. Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis. BMC Cancer. 2022;22(1):255. https:\/\/doi.org\/10.1186\/s12885-022-09342-5.","journal-title":"BMC Cancer"},{"issue":"1","key":"15982_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jtho.2022.09.005","volume":"18","author":"CY Yang","year":"2023","unstructured":"Yang CY, Lin YT, Lin LJ, Chang YH, Chen HY, Wang YP, et al. Stage Shift Improves Lung Cancer Survival: Real-World Evidence. J Thorac Oncol. 2023;18(1):47\u201356. https:\/\/doi.org\/10.1016\/j.jtho.2022.09.005.","journal-title":"J Thorac Oncol"},{"issue":"10125","key":"15982_CR14","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","volume":"391","author":"C Allemani","year":"2018","unstructured":"Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nik\u0161i\u0107 M, et al. Global surveillance of trends in cancer survival 2000\u201314 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023\u201375. https:\/\/doi.org\/10.1016\/S0140-6736(17)33326-3.","journal-title":"Lancet"},{"issue":"7","key":"15982_CR15","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa1916623","volume":"383","author":"N Howlader","year":"2020","unstructured":"Howlader N, Forjaz G, Mooradian MJ, Meza R, Kong CY, Cronin KA, et al. The Effect of Advances in Lung-Cancer Treatment on Population Mortality. N Engl J Med. 2020;383(7):640\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1916623.","journal-title":"N Engl J Med"},{"issue":"1","key":"15982_CR16","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3892\/mco.2021.2439","volume":"16","author":"M Claudio","year":"2021","unstructured":"Claudio M, Mauricio C, Olga B, Gonzalo R, Sandra A, Herman P, et al. Real\u2013world evaluation of molecular testing and treatment patterns for EGFR mutations in non\u2013small cell lung cancer in Latin America. Mol Clin Oncol. 2021;16(1):6. https:\/\/doi.org\/10.3892\/mco.2021.2439.","journal-title":"Mol Clin Oncol"},{"key":"15982_CR17","doi-asserted-by":"publisher","first-page":"842296","DOI":"10.3389\/fonc.2022.842296","volume":"12","author":"T Van Dao","year":"2022","unstructured":"Van Dao T, Diep TB, Le Phuong T, Huggenberger R, Kumar A. Real-World Treatment Patterns and Clinical Outcomes in Patients With Stage III Non-Small-Cell Lung Cancer: Results of KINDLE-Vietnam Cohort. Front Oncol. 2022;12:842296. https:\/\/doi.org\/10.3389\/fonc.2022.842296.","journal-title":"Front Oncol"},{"issue":"7","key":"15982_CR18","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1634\/theoncologist.2017-0659","volume":"23","author":"O Lababede","year":"2018","unstructured":"Lababede O, Meziane MA. The Eighth Edition of TNM Staging of Lung Cancer: Reference Chart and Diagrams. Oncologist. 2018;23(7):844\u20138. https:\/\/doi.org\/10.1634\/theoncologist.2017-0659.","journal-title":"Oncologist"},{"issue":"12","key":"15982_CR19","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1016\/j.jtho.2022.08.011","volume":"17","author":"A Vachani","year":"2022","unstructured":"Vachani A, Carroll NM, Simoff MJ, Neslund-Dudas C, Honda S, Greenlee RT, et al. Stage Migration and Lung Cancer Incidence After Initiation of Low-Dose Computed Tomography Screening. J Thorac Oncol. 2022;17(12):1355\u201364. https:\/\/doi.org\/10.1016\/j.jtho.2022.08.011.","journal-title":"J Thorac Oncol"},{"issue":"9","key":"15982_CR20","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/j.jtho.2021","volume":"16","author":"HTT Tran","year":"2021","unstructured":"Tran HTT, Nguyen S, Nguyen KK, Pham DX, Nguyen UH, Le AT, et al. Lung Cancer in Vietnam. J Thorac Oncol. 2021;16(9):1443\u20138. https:\/\/doi.org\/10.1016\/j.jtho.2021. 06.002 PubMed PMID: 34425998.","journal-title":"J Thorac Oncol"},{"key":"15982_CR21","doi-asserted-by":"publisher","unstructured":"Le QV, Le TP, Luu MN, Nguyen KK, Ngo LL, Do HM et al. From Uptake to Adherence: A Longitudinal Study of Annual LDCT Lung Cancer Screening in Hanoi, Vietnam [SSRN Scholarly Paper]. Rochester, NY: Social Science Research Network; 2026. Available from: https:\/\/papers.ssrn.com\/abstract=6463718https:\/\/doi.org\/10.2139\/ssrn.6463718. [Cited 2026 Mar 29].","DOI":"10.2139\/ssrn.6463718"},{"issue":"6","key":"15982_CR22","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1200\/JCO.21.01626","volume":"40","author":"AC Tan","year":"2022","unstructured":"Tan AC, Tan DSW. Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations. J Clin Oncol. 2022;40(6):611\u201325. https:\/\/doi.org\/10.1200\/JCO.21.01626.","journal-title":"J Clin Oncol"},{"issue":"2","key":"15982_CR23","first-page":"154","volume":"9","author":"Y Shi","year":"2014","unstructured":"Shi Y, Au JSK, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2014;9(2):154\u201362. .0000000000000033 PubMed PMID: 24419411; PubMed Central PMCID: PMC4132036.","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"issue":"11","key":"15982_CR24","doi-asserted-by":"publisher","first-page":"e0143515","DOI":"10.1371\/journal.pone.0143515","volume":"10","author":"Y Shi","year":"2015","unstructured":"Shi Y, Li J, Zhang S, Wang M, Yang S, Li N et al. Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology \u2013 Mainland China Subset Analysis of the PIONEER study. Chai KX, editor. PLOS ONE. 2015;10(11):e0143515. https:\/\/doi.org\/10.1371\/journal.pone.0143515","journal-title":"PLOS ONE"},{"issue":"1","key":"15982_CR25","doi-asserted-by":"publisher","first-page":"100257","DOI":"10.1016\/j.jtocrr.2021.100257","volume":"3","author":"XN Yang","year":"2022","unstructured":"Yang XN, Yan HH, Wang J, Chu XY, Liu ZD, Shen Y, et al. Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study. JTO Clin Res Rep. 2022;3(1):100257. https:\/\/doi.org\/10.1016\/j.jtocrr.2021.100257.","journal-title":"JTO Clin Res Rep"},{"key":"15982_CR26","doi-asserted-by":"publisher","unstructured":"Liao BC, Chiang NJ, Chang GC, Su WC, Luo YH, Chong IW, et al. Registry of Genetic Alterations of Taiwan Non\u2013Small Cell Lung Cancer by Comprehensive Next-Generation Sequencing: A Real-World Cohort Study-Taiwan Cooperative Oncology Group T1521. JCO Glob Oncol. 2024;(10):e2400125. https:\/\/doi.org\/10.1200\/GO.24.00125.","DOI":"10.1200\/GO.24.00125"},{"issue":"24","key":"15982_CR27","doi-asserted-by":"publisher","first-page":"e969","DOI":"10.1097\/MD.0000000000000969","volume":"94","author":"JS Chang","year":"2015","unstructured":"Chang JS, Chen LT, Shan YS, Lin SF, Hsiao SY, Tsai CR, et al. Comprehensive Analysis of the Incidence and Survival Patterns of Lung Cancer by Histologies, Including Rare Subtypes, in the Era of Molecular Medicine and Targeted Therapy: A Nation-Wide Cancer Registry-Based Study From Taiwan. Med (Baltim). 2015;94(24):e969. https:\/\/doi.org\/10.1097\/MD.0000000000000969.","journal-title":"Med (Baltim)"},{"issue":"5","key":"15982_CR28","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1093\/annonc\/mdy474","volume":"30","author":"D Planchard","year":"2019","unstructured":"Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Correction to: Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(5):863\u201370. https:\/\/doi.org\/10.1093\/annonc\/mdy474.","journal-title":"Ann Oncol"},{"key":"15982_CR29","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.lungcan.2021.04.007","volume":"156","author":"D Waterhouse","year":"2021","unstructured":"Waterhouse D, Lam J, Betts KA, Yin L, Gao S, Yuan Y, et al. Real-world outcomes of immunotherapy\u2013based regimens in first-line advanced non-small cell lung cancer. Lung Cancer. 2021;156:41\u20139. https:\/\/doi.org\/10.1016\/j.lungcan.2021.04.007.","journal-title":"Lung Cancer"},{"issue":"1","key":"15982_CR30","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","volume":"11","author":"P Goldstraw","year":"2016","unstructured":"Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WEE, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016;11(1):39\u201351. https:\/\/doi.org\/10.1016\/j.jtho.2015.09.009.","journal-title":"J Thorac Oncol"},{"issue":"9","key":"15982_CR31","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1200\/JCO.1991.9.9.1618","volume":"9","author":"KS Albain","year":"1991","unstructured":"Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol. 1991;9(9):1618\u201326. https:\/\/doi.org\/10.1200\/JCO.1991.9.9.1618.","journal-title":"J Clin Oncol"},{"issue":"3","key":"15982_CR32","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1093\/jnci\/94.3.173","volume":"94","author":"CJ Langer","year":"2002","unstructured":"Langer CJ. Cisplatin-Based Therapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Implications of Eastern Cooperative Oncology Group 5592, a Randomized Trial. CancerSpectrum Knowl Environ. 2002;94(3):173\u201381. https:\/\/doi.org\/10.1093\/jnci\/94.3.173.","journal-title":"CancerSpectrum Knowl Environ"},{"issue":"5","key":"15982_CR33","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1200\/JCO.1995.13.5.1221","volume":"13","author":"M Paesmans","year":"1995","unstructured":"Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. J Clin Oncol. 1995;13(5):1221\u201330. https:\/\/doi.org\/10.1200\/JCO.1995.13.5.1221.","journal-title":"J Clin Oncol"},{"key":"15982_CR34","doi-asserted-by":"publisher","first-page":"1117348","DOI":"10.3389\/fonc.2023.1117348","volume":"13","author":"K Prabhash","year":"2023","unstructured":"Prabhash K, Tan DSW, Soo RA, Sitthideatphaiboon P, Chen YM, Voon PJ, et al. Real-world clinical practice and outcomes in treating stage III non-small cell lung cancer: KINDLE-Asia subset. Front Oncol. 2023;13:1117348. https:\/\/doi.org\/10.3389\/fonc.2023.1117348.","journal-title":"Front Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15982-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15982-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15982-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:52:17Z","timestamp":1779411137000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15982-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15982"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15982-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"assertion":[{"value":"21 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and was reviewed and approved by the Ethics Committee of Nghe An Oncology Hospital. Given the retrospective design and use of anonymized medical records, the requirement for informed consent was waived in accordance with institutional ethical guidelines, including deceased participants. All data were handled confidentially, used exclusively for research purposes, and no personal identifiers were disclosed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"664"}}